Mutational [38] and transcriptomic [39] approaches have not fully clarified yet the role of del(5q) in MDS pathogenesis; however, CSNK1A1 [40] and RPS14 [41] have been identified as strong promising therapeutic targets. The gene discussed is CSNK1A1; the disease is myelodysplastic syndrome.